MM M

79. (Amended) A pharmaceutical composition for the treatment or prevention of a papillomavirus infection or tumor, consisting essentially of a combination of early and late papillomavirus polypeptides consisting of a polypeptide from the E6 region of a papillomavirus, a polypeptide from the E7 region of a papillomavirus, a polypeptide from the L1 region of a papillomavirus and a polypeptide from the L2 region of a papillomavirus.

- 80. (Amended) The pharmaceutical composition according to claim 79, wherein the polypeptide from the early E6 region is a nononcogenic variant of the native E6 protein of a papillomavirus having amino acids 111-115 deleted as compared to said native E6 protein.
- 82. (Amended) The pharmaceutical composition according to claim 80, wherein said human papillomavirus is HPV-16.
 - 83. (Amended) The pharmaceutical composition according to claim 79, wherein the polypeptide from the early E7 region is a nononcogenic variant of the native E7 protein of a papillomavirus having amino acids 21-26 deleted as compared to said native E7 protein.
 - 85. (Amended) The pharmaceutical composition according to claim 83, wherein said human papillomavirus is HPV-16.

- 88. (Amended) The pharmaceutical composition of claim 79, comprising a pharmaceutically acceptable carrier for administration of said composition by injection into humans or into animals.
- 89. (Amended) A method for the treatment or prevention of dysplasia or cancer of the neck of the uterus caused by a papillomavirus, comprising administering an effective amount of the pharmaceutical composition of claim 79, to a patient in need of such treatment.
- 91. (Amended) A pharmaceutical composition for the treatment or prevention of a papillomavirus infection or tumor, consisting essentially of a combination of early and late papillomavirus polypeptides consisting of a polypeptide from the E6 region of a papillomavirus, a polypeptide from the E7 region of a papillomavirus, a polypeptide from the L1 region of a papillomavirus and a polypeptide from the L2 region of a papillomavirus and at least one polypeptide having an immunostimulatory activity selected from the group consisting of interleukin-2, interleukin-7, the co-adhesion molecule B7.1 and the co-adhesion molecule B7.2.
- 92. (Amended) The pharmaceutical composition according to claim 91, wherein the polypeptide from the early E6 region is a nononcogenic variant of the native E6 protein of a papillomavirus having amino acids 111-115 deleted as compared to native E6 protein.

K5

94. (Amended) The pharmaceutical composition according to claim 92, wherein said human papillomavirus is HPV-16.

KF

95. (Amended) The pharmaceutical composition according to claim 91, wherein the polypeptide from the early E7 region is a nononcogenic variant of the native E7 protein of a papillomavirus having amino acids 21-26 deleted as compared to said native E7 protein.

K7

- 97. (Amended) The pharmaceutical composition according to claim 95, wherein said human papillomavirus is HPV-16.
- 104. (Amended) The pharmaceutical composition according to claim 91, comprising a pharmaceutically acceptable carrier for administration of said composition by injection into humans or into animals.

105. (Amended) A method for the treatment or prevention of dysplasia or cancer of the neck of the uterus caused by a papillomavirus, comprising administering an effective amount of the pharmaceutical composition according to claim 91, to a patient in need of

K9

such treatment.

107. (Amended) A method for the treatment or prevention of dysplasia or cancer of the neck of the uterus caused by a papillomavirus, comprising administering an effective

amount of the pharmaceutical composition according to claim 101, to a patient in need of such treatment.

papillomavirus infection or tumor consisting essentially of a combination of polypeptides from the early region of a papillomavirus and at least one polypeptide having an immunostimulatory activity, wherein said combination of polypeptides from the early region of a papillomavirus consists in the E6 and the E7 polypeptides and wherein said polypeptide having an immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, the co-adhesion molecule B7.1 and the co-adhesion molecule B7.2.

109. (Amended) The pharmaceutical composition according to claim 108, wherein the polypeptide from the early region of a papillomavirus is a nononcogenic variant of the native E6 protein of a papillomavirus having amino acids 111-115 deleted as compared to said native E6 protein and/or a nononcogenic variant of the native E7 protein of a papillomavirus having amino acids 21-26 deleted as compared to said native E7 protein.

. 116. (Amended) The pharmaceutical composition of claim 108, comprising a pharmaceutically acceptable carrier for administration of said composition by injection into humans or into animals.

eondd;

Application No. <u>09/043,933</u> Attorney's Docket No. <u>032751-015</u> Page 6

- 117. (Amended) A method for the treatment of dysplasia or cancer of the neck of the uterus caused by a papillomavirus, comprising administering an effective amount of the pharmaceutical composition according to claim 108, to a patient in need of such treatment.
- 118. (Amended) A method for the treatment of dysplasia or cancer of the neck of the uterus caused by a papillomavirus, comprising administering an effective amount of the pharmaceutical composition according to claim 113, to a patient in need of such treatment.
- 119. (Amended) A method for the treatment of a papillomavirus infection, comprising administering an effective amount of the pharmaceutical composition according to claim 108, to a patient in need of such treatment.
- 120. (Amended) A method for the treatment of a papillomavirus infection, comprising administering an effective amount of the pharmaceutical composition according to claim 113, to a patient in need of such treatment.